Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
Crossref DOI link: https://doi.org/10.1186/s10194-019-1069-x
Published Online: 2019-12-27
Published Print: 2019-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Silberstein, Stephen D.
Stauffer, Virginia L.
Day, Katie A.
Lipsius, Sarah
Wilson, Maria-Carmen
Text and Data Mining valid from 2019-12-01
Version of Record valid from 2019-12-27
Article History
First Online: 27 December 2019